1. Home
  2. FLYX vs GANX Comparison

FLYX vs GANX Comparison

Compare FLYX & GANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo flyExclusive Inc.

FLYX

flyExclusive Inc.

N/A

Current Price

$2.47

Market Cap

103.7M

Sector

Finance

ML Signal

N/A

Logo Gain Therapeutics Inc.

GANX

Gain Therapeutics Inc.

N/A

Current Price

$2.96

Market Cap

100.4M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
FLYX
GANX
Founded
2015
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Blank Checks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
103.7M
100.4M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
FLYX
GANX
Price
$2.47
$2.96
Analyst Decision
Strong Buy
Analyst Count
0
6
Target Price
N/A
$8.00
AVG Volume (30 Days)
189.9K
616.6K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
47.95
EPS
N/A
N/A
Revenue
N/A
$55,180.00
Revenue This Year
$9.36
N/A
Revenue Next Year
$15.14
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.90
$1.41
52 Week High
$8.88
$4.34

Technical Indicators

Market Signals
Indicator
FLYX
GANX
Relative Strength Index (RSI) 46.99 66.31
Support Level $1.95 $1.60
Resistance Level $2.65 $3.06
Average True Range (ATR) 0.23 0.24
MACD 0.08 0.10
Stochastic Oscillator 74.46 91.05

Price Performance

Historical Comparison
FLYX
GANX

About FLYX flyExclusive Inc.

flyExclusive Inc is an owner and operator of curated private aviation experiences dedicated to surpassing passenger expectations for quality, convenience, and safety. Its mission is to be the world's majority vertically integrated private aviation company through capital-efficient program growth, an industry pricing model, optimal dispatch availability, in-house training, and a controlled premium customer experience on modernized aircraft. The company has over 100 aircraft in its owned and leased fleet which includes light, midsize, super-midsize, and large jets. As one of the nation's Citation operators, it has curated a versatile fleet of Citation CJ3/CJ3 plus, Citation Excel/XLS/XLS plus, Citation Encore/Encore plus, Citation Sovereign, and Citation X aircraft.

About GANX Gain Therapeutics Inc.

Gain Therapeutics Inc is a biotechnology company developing novel small molecule therapeutics to treat diseases across several therapeutic areas, including, lysosomal storage disorders, central nervous system disorders, metabolic disorders, and oncology. The company's clinical-stage product candidate, GT-02287, is being developed for the treatment of GBA1 Parkinson's disease. The company uses its computational target and drug discovery platform, Magellan, to discover novel allosteric binding sites on proteins implicated in disease and to identify proprietary small molecules that bind these sites to modulate protein function and treat the underlying cause of the disease. Geographically, the company operates in Switzerland, Spain, the United States, and Australia.

Share on Social Networks: